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ABSTRACT
Chronic inﬂammatory responses have long been
observed to be associated with various types of cancer
and play decisive roles at different stages of cancer
development. Inﬂammasomes, which are potent induc-
ers of interleukin (IL)-1β and IL-18 during inﬂammation,
are large protein complexes typically consisting of a
Nod-like receptor (NLR), the adapter protein ASC, and
Caspase-1. During malignant transformation or cancer
therapy, the inﬂammasomes are postulated to become
activated in response to danger signals arising from the
tumors or from therapy-induced damage to the tumor or
healthy tissue. The activation of inﬂammasomes plays
diverse and sometimes contrasting roles in cancer
promotion and therapy depending on the speciﬁc con-
text. Here we summarize the role of different inﬂamma-
some complexes in cancer progression and therapy.
Inﬂammasome components and pathways may provide
novel targets to treat certain types of cancer; however,
using such agents should be cautiously evaluated due
to the complex roles that inﬂammasomes and pro-
inﬂammatory cytokines play in immunity.
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INTRODUCTION
Inﬂammasomes are multimolecular complexes that promote
inﬂammation and inﬂammatory cell death (referred to as
pyroptosis) through the activation of cysteine protease cas-
pase-1 in response to both microbial insults to the host and
endogenous damage-associated molecular patterns
(DAMPS) such as uric acid and extracellular ATP. Inﬂam-
masome complexes are typically comprised of an NLR
which interacts directly with caspase-1 through a caspase
activation and recruitment domain (CARD) or via an adapter
protein, usually apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC; also known
as Pycard), which links the NLR to caspase-1. Different in-
ﬂammasomes are named for the NLR present in the com-
plex, such as the NLRP3-, NLRC4-, NLRP1-, or NLRP6-
inﬂammasome. In addition to the NLR inﬂammasomes,
absent in melanoma 2 (AIM2), one of the PYHIN family
members, is the main component of the AIM2 inﬂammasome
(Schroder and Tschopp, 2010; Di Virgilio, 2013).
Canonical inﬂammasome activation is a two-step process
(Fig. 1A). The ﬁrst step involves the induction of mRNA and
protein expression of pro-IL-1β and pro-IL-18, a procedure
mediated by NF-κB activation. NF-κB-mediated transcription
of pro-IL-1β and pro-IL-18 is induced by activation of toll-like
receptors (TLRs), NOD1 or NOD2 by DAMPS or pathogen-
associated molecular patterns (PAMPS) or signaling by
tumor necrosis factor-α (TNF-α) or IL-1 through their
respective receptors (Chen and Nunez, 2011). Priming also
readies inﬂammasomes for activation; one possible mecha-
nism for this is postulated to be the upregulation of NLRP3
expression in response to LPS. However, a study by Shc-
roder et al. showed that LPS can augment inﬂammasome
activation independently from NLRP3 expression, suggest-
ing that other mechanism for priming exists (Bauernfeind
et al., 2009; Schroder et al., 2012). Indeed, a recent study by
Juliana et al. showed that mitochondria-derived reactive
oxygen species (ROS) can prime the NLRP3 inﬂammasome
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for activation by de-ubiquitination of NLRP3 through a
mechanism involving TLR4/MyD88 signaling. This study also
indicated that signaling by ATP can prime the NLRP3 in-
ﬂammasome through de-ubiquitination (Juliana et al., 2012).
The second step in inﬂammasome activation comes from
NLRs sensing PAMPs or DAMPs. Different inﬂammasomes
are activated by different signals. For example, the NLRP3
inﬂammasome can be activated by various signals including
bacterial pore forming toxins, extracellular ATP, uric acid

















































Figure 1. Inﬂammasome activation and signaling. (A) Inﬂammasomes are activated in two steps. First, priming induces the
expression of pro-IL-1β and pro-IL-18 through the activation of NF-κB. NF-κB is activated by TNF-α and IL-1 or through sensing of
“danger signals” (PAMPs and DAMPs) by TLRs or NOD1/2. Priming also readies the inﬂammasomes for activation through other
unknown mechanism. The second step involves the sensing of PAMPs and DAMPs by NLRs (NLRP3, NLRC4, etc.) or AIM2 through
mechanisms that are not fully understood. Some NLRs, such as NLRP3 and NLRC4, interact with pro-caspase-1 through ASC, while
others, such as NLRP1 can interact directly with caspase-1. Activation of NLRs results in the activation of pro-caspase-1, which when
cleaved can catalyze the proteolytic cleavage and activation of IL-1β and IL-18. Activation of caspase-1 can also induce pyroptotic
cell death, though cleavage of caspase-1 is not required for this process. (B) Non-canonical inﬂammasomes involve activation of
caspase-8 and caspase-11 which can lead to induction of pyroptosis, apoptosis and activation of IL-1β.
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et al., 2006; Dostert et al., 2008; Lamkanﬁ and Dixit, 2009;
Bauernfeind et al., 2011; Franchi and Nunez, 2012). The
NLRC4 inﬂammasome is activated in response to cytosolic
ﬂagellin from various gram-negative bacteria or components
of the bacterial type three or four secretion systems (Maria-
thasan et al., 2004; Franchi et al., 2006; Miao et al., 2006;
Zamboni et al., 2006; Suzuki et al., 2007; Miao et al., 2008;
Chen and Nunez, 2011). Cytosolic double-stranded DNA
from pathogens such as Franscisella tularensis and Listeria
monocytogenes has been demonstrated to activate the AIM2
inﬂammasome (Fernandes-Alnemri et al., 2009; Hornung
et al., 2009; Fernandes-Alnemri et al., 2010; Kim et al., 2010;
Rathinam et al., 2010). For a comprehensive review of in-
ﬂammasome activators, please refer to the recent article
(Bauernfeind and Hornung, 2013). However, the mechanism
of how different inﬂammasomes are activated by these vari-
ous signals is not fully understood. Sensing of danger signals
by NLRs or AIM2 leads to the oligomerization and activation
of caspase-1. Caspase-1 activates pro-IL-1β or pro-IL-18 by
proteolytic cleavage, which in turn promotes inﬂammation
and regulates immune responses (Zitvogel et al., 2012; Di
Virgilio, 2013). Caspase-1 activation can also induce pyrop-
tosis, an inﬂammatory cell death that is accompanied by the
release of IL-1β and IL-18 which elicits local inﬂammation
(Miao et al., 2011). Recent evidence has shown that non-
canonical activation of inﬂammasomes involves caspase-8
or caspase-11. Kayagaki et al. showed that the activation of
caspase-11 in infected macrophages induces pyroptosis as
well as promotes NLRP3 inﬂammasome-mediated process-
ing of IL-1β (Kayagaki et al., 2011). Other studies have shown
that AIM2 and NLRP3 inﬂammasomes can induce apoptosis
through the activation of caspase-8 that interacts with the
inﬂammasome complex via ASC (Sagulenko et al., 2013).
Another recent study has shown that IL-1β is activated in a
caspase-8 dependent manner in dendritic cells following
fungal infection. Caspase-8 is activated in a non-canonical
inﬂammasome complex that consists of CARD9, Malt1, Bcl-
10, caspase-8 and ASC (Gringhuis et al., 2012). We sum-
marized the two steps of canonical inﬂammasome activation
(Fig. 1A) and also the non-canonical inﬂammasome activa-
tion (Fig. 1B).
Carcinomas (cancers derived from epithelial cells) and
adenocarcinomas (cancers derived from epithelium in
glandular tissues) are heterogeneous and consist of many
cell types in addition to cancer cells, including cancer-
associated ﬁbroblasts, different tumor-inﬁltrating immune
cells, adipocytes, endothelial cells, pericytes and others, all
of which can secrete chemokines and cytokines (Griven-
nikov et al., 2010; Coussens et al., 2013). These chemo-
kines and cytokines can directly affect cancer cells or
cause cancer-associated inﬂammation by inducing immune
cell inﬁltration. Myeloid cells, including immature myeloid
cells, neutrophils and macrophages, represent one of the
most frequent immune cells associated with cancer and a
cellular source for inﬂammasome activation and secretion
of IL-1β and IL-18. Cancer-associated inﬂammatory
responses play roles in many aspects of cancer biology
including tumor initiation, progression, metastasis, and
treatment. In this review we will focus on the role of dif-
ferent inﬂammasomes in various malignancies and in tumor
immune responses (Table 1).
GASTROINTESTINAL CANCERS
Cancers of the gastrointestinal (GI) tract are frequently
associated with chronic inﬂammation. The etiological link
between tumorigenesis and the chronic inﬂammation is well
documented for gastric cancer, which is associated with
Helicobacter pylori infection and chronic gastritis, and colo-
rectal cancer, which is frequently associated with inﬂam-
matory bowel disease (IBD) (Ferrone and Dranoff, 2010;
Grivennikov et al., 2010; Zitvogel et al., 2012). As a mediator
of inﬂammation, there is experimental evidence linking
inﬂammasomes and their products to GI cancers.
IL-1β and IL-18, the major products of inﬂammasome
activation, are pro-inﬂammatory cytokines and have been
postulated to be pro-tumorigenic in inﬂammation-induced GI
cancers. Chronic inﬂammation in the stomach due to H.
pylori infection or other causes is mediated by the up-regu-
lation of pro- and anti-inﬂammatory cytokines, including IL-
1β and its naturally occurring receptor antagonist IL-1RN
(Basso et al., 1996; McNamara and El-Omar, 2008). Other
studies have shown that polymorphisms in the IL-1β and/or
IL-1RN genes increase the risk of developing gastric cancer
(El-Omar et al., 2000; Machado et al., 2001; Wang et al.,
2007). Moreover, Tu et al. showed that stomach-speciﬁc
expression of IL-1β in mice induces inﬂammation and
tumorigenesis (Tu et al., 2008). While there is no direct
evidence for the role of IL-1β in colitis-associated colon
cancer (CAC), studies have indicated that IL-1β may pro-
mote tumor growth and invasion by inducing an epithelial to
mesenchymal transition (EMT) and stem cell phenotype thus
increasing the invasiveness of colon cancer cells (Li et al.,
2012). Another study indicated that IL-1β stimulates COX-2
production in cancer associated ﬁbroblasts, leading to an
increase in the proliferation and invasive capabilities of colon
cancer cells (Zhu et al., 2012). These studies suggest that
IL-1β may promote colon tumor progression by acting on
cells in the tumor microenvironment and/or cancer stem
cells. IL-18, however, seems to play a tumor-suppressive
role in CAC. IL-18 deﬁcient mice have increased acute
inﬂammation and tumorigenesis in an azoxymethane/dex-
tran sodium sulphate (AOM/DSS) CAC model, a model that
mimics the pathogenesis of IBD-driven colon tumorigenesis
in human (Salcedo et al., 2010; Zaki et al., 2010b). In addi-
tion, recombinant IL-18 inhibited tumor progression in the
AOM/DSS-induced CAC (Zaki et al., 2010b), suggesting a
protective role for IL-18 from inﬂammation-promoted tumor-
igenesis in the colon. It has been suggested that IL-18 is
critical for repairing colonic epithelium after injury, thus
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leading to an intact bacterial barrier and decreased inﬂam-
mation (Zaki et al., 2010a).
There have been numerous studies on the role of indi-
vidual inﬂammasome components in GI cancers; however,
their speciﬁc roles may be context dependent. Caspase-1
expression is decreased in 19% of gastric cancer cases,
which correlates with stage, lymph node metastasis and
survival (Jee et al., 2005). In support of this etiological study,
Allen et al. reported that Casp1−/−, Asc−/−, and Nlrp3−/− mice
had increased and recurring acute colitis and tumorigenesis
relative to wild-type mice in the CAC model. In contrast,
Nlrc4−/− mice did not exhibit increased colitis and tumori-
genesis (Allen et al., 2010). Furthermore, they reported that
NLRP3-inﬂammasome activation in hematopoietic cells is
critical for the tumor suppressive function (Allen et al., 2010),
which has been attributed to IL-18 production (Salcedo et al.,
2010; Zaki et al., 2010b). Interestingly, in contrast, Hu et al.
reported that Casp1−/− and Nlrc4−/− mice, rather than Nlrp3−/−
mice, showed greater tumor load than wild-type mice (Hu
et al., 2010, 2011). The tumor suppressor effect of the
NLRC4-inﬂammasome seems to be primarily from NLRC4
expression in epithelial cells (Hu et al., 2011). Additionally,
colonic epithelial cells deﬁcient in caspase-1 bear greater
resistance to apoptosis and increased proliferation relative to
colon epithelial cells from wild-type mice (Hu et al., 2010). The
tumor-suppressing function of inﬂammasomes does not
always correlate with their role in promoting or suppressing
DSS-induced inﬂammation; rather some studies have repor-
ted that Casp1−/− and Nlrp3−/− mice have decreased DSS-
induced inﬂammation and colitis (Siegmund et al., 2001;
Bauer et al., 2010).
NLRP6, another NLR family member, can also suppress
tumorigenesis in the AOM/DSS CAC model, likely through
secretion of IL-18 from hematopoietic cells (Chen et al., 2011),
or regulation of wound healing by myoﬁbroblasts (Normand
et al., 2011). In support of this, a study by Ellinav et al. showed
that Nlrp6−/− mice had reduced IL-18 levels and exacerbated
DSS-induced colitis compared to wild-type mice, and devel-
oped spontaneous colonic neoplasia. NLRP6, similar to
NLRC4 (Hu et al., 2011), is also expressed in epithelial cells
suggesting that NLRP6 may suppress tumorigenesis by the
secretion of IL-18 from epithelial cells and not hematopoietic
cells (Elinav et al., 2011). NLRP12 has also been implicated to
play a role in inﬂammation and tumorigenesis in the colon.
Studies have shown thatNlrp12−/−mice are more susceptible
to both DSS-induced colitis and AOM/DSS-induced
Table 1. Studies on the roles of inﬂammasomes in inﬂammation and cancer
Inﬂammasome components
or mouse models
Impacts on inﬂammation and cancer References
Gastric cancer Stomach speciﬁc Transgenic
expression of IL-1β
Induces stomach inﬂammation and
tumorigenesis
Tu et al., 2008
IL-1β Promotes tumor growth and invasion Li et al., 2012;
Zhu et al., 2012
IL-18−/− mouse Increased AOM/DSS-induced inﬂammation and
tumorigenisis
Salcedo et al., 2010;
Zaki et al., 2010b
Casp1−/− mouse Increased AOM/DSS-induced inﬂammation and
tumorigenisis
Allen et al., 2010;
Zaki et al., 2010a;
Dupaul-Chicoine
et al., 2010
Asc−/− mouse Increased AOM/DSS-induced inﬂammation and
tumorigenisis
Colon cancer Nlrp3−/− mouse Increased AOM/DSS-induced inﬂammation and
tumorigenisis
Nlrc4−/− mouse No discernible phenotype
Nlrc4−/− mouse Increased AOM/DSS-induced inﬂammation and
tumorigenisis
Hu et al., 2011
Nlrp3−/− mouse No discernible phenotype
Nlrp6−/− mouse Increased AOM/DSS inﬂammation and
tumorigenesis
Chen et al., 2011;
Elinav et al., 2011;
Normand et al.,
2011
IL-1β Promotes tumor growth, angiogenesis, invasion
and metastasis
Dunn et al., 2012
Casp1−/− mouse Reduced chemical induced tumorigenesis Drexler et al., 2012
Melanoma Myeloid cell-speciﬁc Asc deletion Increased chemical-induced tumorigenesis
Keratinocyte-speciﬁc Asc deletion Reduced chemical-induced tumorigenesis
NLRP3 inﬂammasome activation Promotes progression and metastasis Okamoto et al., 2010
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tumorigenesis, indicating a tumor suppressor function for
NLRP12 inCAC (Zaki et al., 2011;Allen et al., 2012). However,
it is not known if NLRP6 or NLRP12 can form a functional
inﬂammasome and further experimental support is required to
make a deﬁnitive conclusion.
The inconsistencies between these various studies may
be explained by differences in methodologies or animal
facilities resulting in an altered composition of microbiota
which can be sensed by different inﬂammasomes. The role
of individual inﬂammasomes in inﬂammation-driven GI
tumorigenesis may be speciﬁc to different inﬂammation-
causing bacteria or their products present in the GI tract.
SKIN CANCERS
The greatest environmental risk factor for skin cancer
including melanoma is ultraviolet radiation which can pro-
mote cancer by causing DNA damage, immunosuppression
and inﬂammation (Kanavy and Gerstenblith, 2011; Dunn
et al., 2012). The involvement of inﬂammation in melanoma,
the most malignant type of skin cancer, is indicated by the
upregulation of inﬂammatory cytokines including IL-6, IL-8,
CCL5, and IL-1β, all of which can be regulated by active
IL-1β (Raman et al., 2007; Dinarello, 2009). Elevated level of
active IL-1β in melanoma cells has been shown to act in both
paracrine and autocrine manners to promote tumor growth,
angiogenesis, recruitment of macrophages and immune
suppresser cells, invasion and metastasis (Dunn et al.,
2012). In addition, a recent study by Okamoto et al. indicates
that the expression and secretion of active IL-1β in mela-
noma becomes increasingly autonomous during disease
progression, which seems to be driven by constitutive acti-
vation of the NLRP3 inﬂammasome (Okamoto et al., 2010).
The function of active inﬂammasomes in skin cancer may
differ depending on the cell type in which the inﬂammsomes
are activated, as well as the stage of tumors. In a recent
study, it was reported that while Il1r1−/− and Casp1−/− mice
developed fewer tumors and had delayed tumor incidence
compared to WT mice in a chemical-induced skin cancer
model, Asc−/− mice had no discernible phenotype when
compared to WT animals. To further investigate the function
of ASC in skin carcinogenesis, the investigators generated
Asc-tissue-speciﬁc knockout mice in either keratinocytes or
myeloid cells. The authors found that myeloid cell-derived
ASC promotes tumor incidence while keratinocyte-derived
ASC inhibits it. These results suggest a tissue speciﬁc role
for inﬂammasomes in skin carcinogenesis, or ASC pos-
sesses other functions in keratinocytes to suppress tumori-
genesis (Drexler et al., 2012). In a separate study, Liu et al.
reported different functions for ASC in metastatic melanoma
cells versus non-metastatic cells. In non-metastatic mela-
noma cells, ASC expression leads to decreased NF-κB
activity and reduced tumorigenesis; however, ASC expres-
sion in metastatic melanoma cells increases NF-κB activity
resulting in increased expression of pro-IL-1β, inﬂammasome
mediated secretion of active IL-1β and enhances tumori-
genesis (Liu et al., 2013). Previously it was reported that
ASC can either inhibit or promote NF-κB activity depending
on the expression of other PAAD/PYRIN-family proteins
such as pyrin or NLRP3 (Stehlik et al., 2002). Therefore, it is
possible that the effect of ASC expression in primary versus
metastatic melanoma cells may be due to the differential
expression of PAAD-family proteins.
INFLAMMASOME ACTIVATION IN OTHER CANCERS
In addition to GI and skin cancers, inﬂammasome activation
may play important roles in other cancers including breast
cancer and hepatitis C virus (HCV)-associated hepatocellular
carcinoma (HCC). While there is no direct evidence showing
the involvement of inﬂammasomes in breast cancer, it has
been reported that IL-1β plays a role in tumorigenesis and
progression of breast cancer. IL-1R1 expression is higher in
ductal carcinoma in situ (DCIS) and invasive ductal carci-
noma (IDC) relative to normal tissue (Pantschenko et al.,
2003). Polymorphisms of IL-1R1 and IL-1β have been
associated with disease progression and prognosis (Snoussi
et al., 2005; Liu et al., 2010). Other studies have shown that
elevated level of IL-1β in breast cancer is associated with a
more aggressive phenotype and higher tumor grade (Jin
et al., 1997; Chavey et al., 2007). In a mouse model of human
breast cancer, ﬁbroblast growth factor receptor 1-induced
mammary tumorigenesis is associated with local production
of IL-1β and can be blocked by treatment with an IL-1β
neutralizing antibody (Reed et al., 2009).
The involvement of the inﬂammasome in HCC may
depend on the carcinogen driving the process. Limited lit-
erature indicates that necrotic hepatocytes can secrete
IL-1α, the major cytokine involved in diethylnitrosamine (DEN)-
induced HCC (Sakurai et al., 2008). However, HCV infection,
one of the most potent HCC inducers in human, activates the
NLRP3 inﬂammasome in Kupffer cells (liver resident mac-
rophages) and releases active IL-1β (Burdette et al., 2012;
Negash et al., 2013). Although the HCV-induced HCC ani-
mal model is yet-to-be established, it is reasonable to
speculate that HCV-associated IL-1β production may act in a
similar manner as IL-1α for HCC development.
IMMUNE REGULATION BY INFLAMMASOMES
DURING CANCER DEVELOPMENT AND THERAPY
Apart from distinct roles of inﬂammasomes in cancer men-
tioned above, inﬂammasome-mediated processing and
secretion of IL-1β and IL-18 is critical in both innate and
adaptive immune responses. Therefore, it is not surprising to
ﬁnd that inﬂammasomes can modulate tumor immunity
during development and therapy (Eisenbarth and Flavell,
2009; Zitvogel et al., 2012). Studies have shown that IL-1β
plays an important role in the expansion of myeloid derived
suppressor cells (MDSC) in the bone marrow and their
REVIEW Ryan Kolb et al.









recruitment during chronic inﬂammation and tumorigenesis
(Tu et al., 2008; Bunt et al., 2009; Elkabets et al., 2010;
Sevko and Umansky, 2013). The role of inﬂammasomes in
MDSC recruitment and immunosuppression is further sup-
ported by a study reporting that tumors derived from Nlrp3−/−
mice exhibit less inﬁltrating MDSC than those from WT mice
(van Deventer et al., 2010). Tumor-associated MDSC may
suppress natural killer (NK) cells, which would explain why
loss of NLRP3 increases the anti-metastatic function of NK
cells in a B16-F10 lung metastasis model (Chow et al.,
2012). IL-18 can also suppress the anti-metastatic effect of
NK-cells and IL-18 depletion boosts immune surveillance
function of NK cells in B16-F10 melanomas and CT26 colon
cancers (Terme et al., 2011). These studies indicate a role of
inﬂammasomes in immunosuppression during tumorigene-
sis and metastasis.
Apart from their roles in immunosuppression during
tumorigenesis and metastasis, inﬂammasomes may formu-
late the response to anti-tumor vaccines. A study by van
Deventer et al. reported that Nlrp3−/− mice had increased
survival when treated with a dendritic cell (DC) derived
vaccine against B16-F10 melanoma cells compared to their
wild-type counterparts. This increase in survival of Nlrp3−/−
mice was associated with a decrease in the number of
tumor-associated MDSC. Furthermore, depletion of MDSC
in wild-type mice using an anti-GR-1 antibody improved
survival in conjunction with the anti-tumor vaccine (van De-
venter et al., 2010). This study suggests that the immuno-
suppressive role of the NLRP3 inﬂammasome may reduce
the effectiveness of DC derived anti-tumor vaccines.
In addition to inducing apoptosis of cancer cells, some
chemotherapeutic agents such as γ-irradiation, anthracy-
clines and oxaliplatin can induce pyroptosis which increases
their efﬁciency at reducing tumor burden (Locher et al.,
2010). Necrotic cell death results in the release of ATP from
dying tumor cells into the extracellular space (Martins et al.,
2009), which can be sensed by purinergic receptors on the
surface of DCs, resulting in activation of tumor-antigen
speciﬁc type-1 T helper cells (Th1) and cytotoxic CD8 Tcells
(Idzko et al., 2002; Elliott et al., 2009; Zitvogel et al., 2012).
Activation of Th1 is mediated by ATP-dependent activation
of NLRP3 inﬂammasome in DC and the release of IL-1β
(Ghiringhelli et al., 2009; Iyer et al., 2009; Zitvogel et al.,
2012). In line with the above evidence, anthracyclines and
other chemotherapy agents cannot induce immunogenic cell
death in mice lacking components of NLRP3 inﬂammasome
including ASC, NLRP3, and Caspase-1 (Ghiringhelli et al.,
2009). Furthermore, studies have shown that blocking IL-1β
signaling reduces the anti-tumor effect of anthracyclines and
oxaliplatin (Mattarollo et al., 2011).
PERSPECTIVE
The complex roles of inﬂammasome activation in cancer
development or therapyhavestarted togain attention in recent
years. During cancer development or treatment, inﬂamma-
somes can sense various signals including those not associ-
ated with cancer cells. Intestinal microbiota represents one of
those non-cancer associated signals that may activate dif-
ferent inﬂammasomes with different potencies. It is thus not
surprising that the same genetically manipulated animals in
different animal facilities yield different, sometimes contrasting
results in terms of inﬂammation and GI cancers. Composition
of intestinal microbiota, however, may also affect cancers
distal to the GI track due to the global effect of inﬂammasome
activation and IL-1β or IL-18 secretion.
The roles of inﬂammasome activation in cancer are also
tissue-speciﬁc. One good example is Asc depletion in a car-
cinogen-induced skin cancer model, where Asc depletion in
myeloid cells inhibits skin tumor development but deletion in
keratinocytes promotes it. In a colitis-associated colon cancer
model, NLRP3 inﬂammasome works through myeloid cells
whereas NLRC4 inﬂammasome plays a role in epithelial cells.
Thus interpretation of the roles of different inﬂammasomes in
cancer development has to take into account tissue types.
Evaluation of the tissue speciﬁc roles of different inﬂamma-
some components will ultimately depend on the generation of
conditional knockout mice for various molecules.
Compounds that target inﬂammasomes, such as IL-1β
neutralizing antibodies, recombinant IL-1RN (anakinra) and
IL-18 binding protein, have been developed,while others such
as small molecule inhibitors that target caspase-1 are cur-
rently being developed (GreenandKroemer, 2005;Srivastava
et al., 2010; Dinarello, 2011). The use of any therapy targeting
the inﬂammasomes to treat cancer will depend on being able
to determine when such therapies will be beneﬁcial and when
they will be detrimental due to the context speciﬁc function of
the inﬂammasome in cancer. For example, blocking IL-1β
signaling in metastatic melanoma cells and in breast cancer
may be beneﬁcial because IL-1β is indicated to promote tumor
progression and metastasis in these tumors. However,
blocking IL-1β may decrease the efﬁcacy of the traditional
chemotherapy agents if used in combination. Inﬂammasomes
may provide a promising target for cancer therapy and pre-
vention, though additional studies are required to determine
the context-speciﬁc functions of inﬂammasomes during can-
cer development and progression.
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